Clinical Data IDEAYA/Servier PKC drug aces uveal melanoma trial PharmaphorumServier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026. Clinical DataOncologyRead full story Post navigation Previous: AbbVie enters world of pain in up to $715M deal with China’s HaiscoNext: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
